Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2022 11:50 ET | Source: Curium

Curium’s Customers to Benefit From Mo-99 Production Restart

PARIS, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the restarting of a production cycle at the HFR reactor in Petten,...
November 22, 2022 00:01 ET | Source: Curium

Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.

ST. LOUIS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that it intends to submit updated labeling to the U.S. Food and Drug Administration...
November 08, 2022 13:05 ET | Source: Curium

Nuclear Medicine Outlook: Proven Molybdenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients

Measures in place minimize impact of near-term molybdenum-99 shortageMore than ten years of Mo-99 supply chain resilienceCooperation, investment, and facility upgrades for the benefit of patients ...
June 27, 2022 01:00 ET | Source: Curium

Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the European Medicines Agency

Submission follows the completion of Phase III PYTHON clinical trial of [18F]-DCFPyL for recurrent prostate cancer in Europe in May 2022Phase III PYTHON clinical trial results to be presented at the...
May 12, 2022 01:05 ET | Source: Curium

Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial

ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium...
May 03, 2022 01:05 ET | Source: Curium

Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients

ST. LOUIS, May 03, 2022 (GLOBE NEWSWIRE) -- Curium announced today it has successfully enrolled and dosed patients in the ECLIPSE Trial. ECLIPSE is a Phase 3, multi-center, open-label, randomized...
April 19, 2022 01:00 ET | Source: Curium

Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now...
April 05, 2022 01:05 ET | Source: Curium

Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.

ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug...
January 25, 2022 00:00 ET | Source: Curium

Curium to become major player in the supply on non carrier added Lu-177

LONDON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added...